{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:53:25Z","timestamp":1789325605086,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007875","name":"a Tulane University Carol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.12.053","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T13:53:59Z","timestamp":1547042039000},"page":"808-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-8135","authenticated-orcid":false,"given":"Sarah M.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Pociask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Morici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.12.053_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Cont Hospit Epidemiol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/518460","article-title":"Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia","volume":"28","author":"Weber","year":"2007","journal-title":"Infect Cont Hospit Epidemiol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0015","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic Resistant Threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/index.html."},{"key":"10.1016\/j.vaccine.2018.12.053_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1586\/14760584.2014.890053","article-title":"Vaccines for Pseudomonas aeruginosa: a long and winding road","volume":"13","author":"Priebe","year":"2014","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.12.053_b0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2002.01731.x","article-title":"Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response","volume":"127","author":"Moser","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jaci.2005.09.023","article-title":"Pulmonary TH2 response in Pseudomonas aeruginosa\u2013infected patients with cystic fibrosis","volume":"117","author":"Hartl","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0035","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.4049\/jimmunol.181.7.4965","article-title":"IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa","volume":"181","author":"Priebe","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1183\/09031936.99.14511369","article-title":"Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation","volume":"14","author":"Wojnarowski","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2018.12.053_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/infdis\/jis657","article-title":"Collaboration between macrophages and vaccine-induced CD4+ T Cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia","volume":"207","author":"Kamei","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.053_b0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2015.11.008","article-title":"Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine","volume":"82","author":"Tozuka","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.vaccine.2018.12.053_b0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fimmu.2013.00254","article-title":"Tissue specific heterogeneity in effector immune cell response","volume":"4","author":"Tufail","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.it.2004.05.008","article-title":"Tissue targeting of T cells by DCs and microenvironments","volume":"25","author":"Dudda","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mi.2011.6","article-title":"Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae","volume":"4","author":"Novotny","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0070","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/IAI.00181-12","article-title":"The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens","volume":"80","author":"Norton","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0075","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0080","first-page":"549","article-title":"Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+ T cells following parenteral immunization","volume":"2","author":"Frederick","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0085","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2012.10.033","article-title":"Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization","volume":"31","author":"Novotny","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0090","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","article-title":"Cholera Toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP\u2013protein kinase A and inflammasome-dependent IL-1 signaling","volume":"194","author":"Larena","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0095","unstructured":"Hancock REW. Hancock Laboratory Methods. http:\/\/cmdr.ubc.ca\/bobh\/methods\/."},{"key":"10.1016\/j.vaccine.2018.12.053_b0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/01902140600817465","article-title":"Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation","volume":"32","author":"Lakatos","year":"2006","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.vaccine.2018.12.053_b0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2500\/108854101778148737","article-title":"MCP-1 and RANTES are mediators of acute and chronic inflammation","volume":"22","author":"Conti","year":"2001","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.vaccine.2018.12.053_b0110","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN- -inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T Cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.184.2.473","article-title":"Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level","volume":"184","author":"Sornasse","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.12.053_b0120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1084\/jem.178.3.1041","article-title":"Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor\/IL-12 synthesis in accessory cells","volume":"178","author":"D'Andrea","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.12.053_b0125","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.4049\/jimmunol.0903151","article-title":"IL-7 Promotes T Cell viability, trafficking, and functionality and improves survival in sepsis","volume":"184","author":"Unsinger","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.coi.2013.03.011","article-title":"Th17 cell based vaccines in mucosal immunity","volume":"25","author":"Kumar","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.immuni.2011.10.018","article-title":"Th17 Cells mediate clade-specific, serotype-independent mucosal immunity","volume":"35","author":"Chen","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.12.053_b0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1189\/jlb.4A1215-581R","article-title":"Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia","volume":"101","author":"Shindo","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0145","doi-asserted-by":"crossref","first-page":"e51718","DOI":"10.1371\/journal.pone.0051718","article-title":"The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T Cells specific for bacterial vaccine antigens","volume":"7","author":"Leach","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.12.053_b0150","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/CVI.00036-10","article-title":"Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine","volume":"17","author":"Lu","year":"2010","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0155","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/IAI.01139-10","article-title":"Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection","volume":"79","author":"Kamei","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0160","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0264-410X(98)00420-4","article-title":"A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa","volume":"17","author":"Knapp","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0165","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/S0264-410X(00)00550-8","article-title":"Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers","volume":"19","author":"Larbig","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0928-8244(03)00094-4","article-title":"Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule","volume":"37","author":"G\u00f6cke","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0928-8244(03)00072-5","article-title":"Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients","volume":"37","author":"Mansouri","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0180","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2003.11.029","article-title":"Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections","volume":"22","author":"Baumann","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1465-9921-8-57","article-title":"Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I\/II study","volume":"8","author":"Baumann","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.vaccine.2018.12.053_b0190","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.vaccine.2009.03.010","article-title":"Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease","volume":"27","author":"Sorichter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0195","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/IAI.58.7.2241-2244.1990","article-title":"Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli","volume":"58","author":"Finke","year":"1990","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0200","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41598-017-04029-5","article-title":"Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.12.053_b0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jmii.2016.08.014","article-title":"Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa","volume":"51","author":"Hassan","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.vaccine.2018.12.053_b0210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.vaccine.2012.12.063","article-title":"Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA\/I over expressing bacteria and recombinantly produced LTB\/CTB hybrid protein","volume":"31","author":"Lundgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0215","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1128\/IAI.72.7.4052-4060.2004","article-title":"Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin","volume":"72","author":"Bowe","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0220","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4049\/jimmunol.1302743","article-title":"Intradermal delivery of Shigella IpaB and IpaD Type III secretionpProteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes","volume":"192","author":"Heine","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.053_b0225","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/IAI.70.3.1443-1452.2002","article-title":"Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice","volume":"70","author":"Jakobsen","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0230","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1128\/IAI.67.12.6270-6280.1999","article-title":"Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells","volume":"67","author":"Ryan","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0235","doi-asserted-by":"crossref","unstructured":"FELASA working group on revision of guidelines for health monitoring of rodents and rabbits, M\u00e4hler Convenor M, Berard M, Feinstein R, Gallagher A, Illgen-Wilcke B, Pritchett-Corning K, Raspa M. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Laboratory Animals, 3rd ed. 48:178\u2013192; 2014.","DOI":"10.1177\/0023677213516312"},{"key":"10.1016\/j.vaccine.2018.12.053_b0240","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1128\/IAI.68.9.5306-5313.2000","article-title":"Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants","volume":"68","author":"Scharton-Kersten","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0245","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1128\/IAI.01412-07","article-title":"Respiratory francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells","volume":"76","author":"Woolard","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.12.053_b0250","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2009.03.018","article-title":"Intradermal immunization improves protective efficacy of a novel TB vaccine candidate","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.053_b0255","unstructured":"Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation; 2015."},{"key":"10.1016\/j.vaccine.2018.12.053_b0260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/sur.2018.233","article-title":"Progress toward the elusive pseudomonas aeruginosa vaccine","volume":"19","author":"Merakou","year":"2018","journal-title":"Surg Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T04:09:49Z","timestamp":1606018189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1930009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X1930009X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}